Surgery confers survival benefit in De Novo metastatic soft tissue sarcoma patients with low Ki67 or low total lesion glycolysis: a combined PET/CT and clinicopathological analysis - Takeaways - MDSpire

Surgery confers survival benefit in De Novo metastatic soft tissue sarcoma patients with low Ki67 or low total lesion glycolysis: a combined PET/CT and clinicopathological analysis

  • By

  • Shaoli Li

  • Xin Zheng

  • Menglei Jin

  • Hui Wang

  • Rui Bai

  • Ying Dong

  • July 10, 2026

  • 0 min

Share

  • 1

    Soft tissue sarcomas account for less than 1% of adult cancers but contribute significantly to cancer-related morbidity and mortality.

  • 2

    The role of surgical intervention for primary tumors in de novo metastatic soft tissue sarcoma remains controversial and poorly defined.

  • 3

    This study evaluated the prognostic value of ¹⁸F-FDG PET/CT metabolic parameters in patients with de novo metastatic soft tissue sarcoma.

  • 4

    A total of 40 patients with de novo metastatic soft tissue sarcoma were included in the retrospective analysis of this study.

  • 5

    The study aimed to explore the interaction between PET/CT-derived metrics and the potential survival benefit of primary tumor surgery.

Original Source(s)

Surgery confers survival benefit in De Novo metastatic soft tissue sarcoma patients with low Ki67 or low total lesion glycolysis: a combined PET/CT and clinicopathological analysis

  • by Shaoli Li, Xin Zheng, Menglei Jin, Hui Wang, Rui Bai, Ying Dong

  • July 10, 2026

Related Content

Impact of tumor immunotherapy on kidney injury and multi-organ outcomes: a mechanistic and clinical perspective

Editorial: Advancing diagnostic excellence in early lung cancer detection

Small intestinal metastasis of triple-negative breast cancer mimicking lymphoma: imaging findings and case report